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Oxidative stressFamilial British dementia (FBD) is an early-onset non-amyloid-β (Aβ) cerebral amyloidosis that presents with
severe cognitive decline and strikingly similar neuropathological features to those present in Alzheimer's disease
(AD). FBD is associated with a T to A single nucleotide transition in the stop codon of a gene encoding BRI2,
leading to the production of an elongated precursor protein. Furin-like proteolytic processing at its C-terminus
releases a longer-than-normal 34 amino acid peptide, ABri, exhibiting amyloidogenic properties not seen in
its 23 amino acid physiologic counterpart Bri1–23. Deposited ABri exhibits abundant post-translational
pyroglutamate (pE) formation at the N-terminus, a feature seen in truncated forms of Aβ found in AD deposits,
and co-exists with neuroﬁbrillary tangles almost identical to those found in AD. We tested the impact of the
FBD mutation alone and in conjunction with the pE post-translational modiﬁcation on the structural properties
and associated neurotoxicity of the ABri peptide. The presence of pE conferred to the ABrimolecule enhanced hy-
drophobicity and accelerated aggregation/ﬁbrillization properties. ABri pE was capable of triggering oxidative
stress, loss of mitochondrial membrane potential and activation of caspase-mediated apoptotic mechanisms in
neuronal cells, whereas homologous peptides lacking the elongated C-terminus and/or the N-terminal pE
were unable to induce similar detrimental cellular pathways. The data indicate that the presence of N-
terminal pE is not in itself sufﬁcient to induce pathogenic changes in the physiologic Bri1–23 peptides but that
its combination with the ABri mutation is critical for the molecular pathogenesis of FBD.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The aberrant aggregation and/or folding of proteins is a recurrent
problem of many proteopathies, including amyloidosis. Alzheimer's
disease (AD), the most common form of amyloidosis and dementia in; ANS, 8-anilinonaphthalene-1-
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ueda.rostagno@nyumc.orghumans, is characterized by the deposition of amyloid-β (Aβ) in the
brain parenchyma and cerebral vasculature as well as by the presence
of hyperphosphorylated tau in intraneuronal neuroﬁbrillary tangles [1,
2]. Although it is unclearwhat primarily triggers and drives the progres-
sion of AD, strong evidence supports a pathogenic role of Aβ oligomeric
conformations [3–6]. According to the current amyloid cascade hypoth-
esis, changes in the brain Aβ homeostasis lead to the accumulation of
oligomers capable of inducing oxidative injury, inﬂammation, synaptic
dysfunction, tau hyperphosphorylation, and ultimately neurodegenera-
tive cell death. In support of the relevance of Aβ for disease pathogene-
sis, individuals with Down's syndrome –who feature an overexpression
of the Aβ precursor protein (APP) due to the presence of the extra
chromosome 21 – develop AD pathology by middle age [7,8]. In this
line, familial APPmutations exhibiting elevated Aβ production translate
into an earlier onset of the disease [9–11] and transgenic animalmodels
of such familial mutations develop amyloid pathology and cognitive
deﬁcits in the absence of neuroﬁbrillary tangles [12].
Perhaps the strongest support for the amyloid cascade hypothesis
comes from an autosomal dominant form of non-Aβ cerebral
amyloidosis – familial British dementia (FBD) – which shares many
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ized by progressive dementia, cerebellar ataxia, and spastic tetraparesis
with an age of onset in the fourth to ﬁfth decade of life and a duration of
about 7 to 9 years [13]. Neuropathologically, affected individuals
present with severe widespread amyloid deposition in the vasculature
of the brain and spinal cord, perivascular plaques, periventricular
white matter changes, amyloid plaques predominantly in the limbic
areas, and hippocampal neuroﬁbrillary tangles morphologically and
biochemically identical to those found in AD [14–16]. FBD is associated
with a single nucleotide transition (T to A) at the stop codon of the BRI2
gene located on the long arm of chromosome 13 encoding a 266 amino
acid long transmembrane protein BRI2 with a presently undeﬁned
physiological function. This stop-to-arginine mutation produces an
elongated 277 amino acid precursor protein, ABriPP, which is cleaved
at peptide bond 243–244 by furin-like normal proteolytic processing
to release a 34 amino acid amyloidogenic peptide, ABri. In non-carrier
individuals, BRI2 is also cleaved in the same position to produce a 23
amino acid circulating peptide, Bri1–23 or WT Bri [16–20].
A soluble form of ABri is also present in the circulation of affected in-
dividuals [14,17,18]. Interestingly, while this circulating form bears a
regularN-terminal glutamate residue, biochemical analysis of deposited
ABri reveals the presence of a post-translationally modiﬁed N-terminus
in which the free amino group of the glutamate moiety is cyclized to
form pyroglutamate (pE), a reaction that proceeds through the action
of glutaminyl cyclase [21,22]. N-terminal pE formation is a common
ﬁnding in the heavy and light chains of immunoglobulin molecules
(http://www.ncbi.nlm.nih.gov/protein) and has been reported for
several truncated forms of Alzheimer's Aβ peptide, speciﬁcally AβpE3
and AβpE11. The loss of a negative charge occurring as a result of the
posttranslational modiﬁcation increases the β-sheet content, aggrega-
tion propensity, hydrophobicity, and resistance to degradation by pepti-
dases in the Aβmolecule [23,24]. Thesemodiﬁed forms of Aβ have been
shown to be more neurotoxic than full-length, unmodiﬁed Aβ [25–28].
Accordingly, pE-containing Aβ is more abundant in the AD brain
compared to healthy age-matched controls, suggesting an important
role of this modiﬁcation in the pathogenesis of this disease [29–33].
Previous studies indicate that ABri pE exhibits rapid ﬁbrillogenesis
and neurotoxicity [34–39] while the normal circulating Bri1–23 lacks
β-sheet secondary structure and is not prone to aggregation [34,38].
The formation of the N-terminal pyroglutamate moiety has been
shown to inﬂuence the aggregation propensity of ABri as well as of
the other BRI2-related amyloid ADan, and in the latter, enhance
oligomer formation and impair synaptic potentiation [25]. The present
work includes a comprehensive analysis of the inﬂuence of the FBDmu-
tation as well as the posttranslational pE formation on the aggregation/
ﬁbrillization and associated neurotoxicity of ABri. A detailed analysis of
the cellular mechanisms elicited by the oligomeric amyloid assemblies
revealed the engagement of mitochondrial pathways involving the
release of cytochrome c (cyt c), loss of the organelle membrane
potential, and oxidative stress that in turn lead to the induction of
caspase 9-mediated apoptotic pathways.2. Materials and methods
2.1. Peptide synthesis
Synthetic homologues of ABri and Bri1–23, both with either an
N-terminal pE or an N-terminal glutamate, as well as Aβ42 were syn-
thesized using N-tert-butyloxycarbonyl chemistry by James I. Elliott at
Yale University (New Haven, CT) and puriﬁed by reverse phase-high
performance liquid chromatography on a Vydac C4 column (Western
Analytical, Murrieta, CA). Molecular masses were corroborated by
matrix-assisted laser desorption ionization time-of-ﬂight (MALDI-
TOF) mass spectrometry, and concentrations were assessed by amino
acid analysis, as previously reported [40].2.2. Circular dichroism spectroscopy
To evaluate peptide solubilization and disruption of pre-existing
conformationswith potential to seed and enhance subsequent aggrega-
tion, ABri and Bri1–23 (either N-terminal pE or E) synthetic homologues
were incubated at a concentration of 1 mg/ml in hexaﬂuoroisopropanol
(HFIP; Sigma Chemical Co., St. Louis, MO), a pretreatment that breaks
down β-sheet structures and disrupts hydrophobic forces leading
tomonodisperse amyloid subunit preparations [41]. Formation of stable
α-helix structureswasmonitored over time until superimposed circular
dichroism (CD) scans were obtained in subsequent days. To measure
changes in peptide secondary structure over time at physiological
salt concentrations the lyophilized HFIP-pretreated peptides were
reconstituted to 1 mM in 1% ammonium hydroxide followed by further
dilution in a 10mMphosphate buffer, pH 7.4, containing 150 mM sodi-
um ﬂuoride to a ﬁnal concentration of 50 μM. Under both conditions,
spectra in the far-ultraviolet light (wavelength range: 190–260 nm;
band-width 1 nm; intervals 1 nm; scan rate 60 nm/min) yielded by
the different peptides at various time points of aggregation (up to
2 days) were recorded at 24 °C with a Jasco J-720 spectropolarimeter
(Jasco Inc., Easton, MD). A 0.2 mm path quartz cell was used for the
samples in HFIP, while a 1mmpath quartz cell was used for the samples
in salt-containing buffer. For each sample, 15 consecutive spectra were
obtained and averaged, and thebaseline readingwas subtracted. Results
are expressed in terms of molar ellipticity (deg·cm2·dmol−1), as
previously described [40].
2.3. Peptide solubilization and aggregation
Synthetic ABri and Bri1–23 homologues (with or without N-
terminal pE) were pretreated in HFIP at a concentration of 1 mg/ml
for 4–7 days, depending on the inherent characteristics of each mole-
cule. Following lyophilization, peptides were thoroughly dissolved to
10mM in dimethyl sulfoxide (DMSO, Sigma) then to 1mM in deionized
water followed by further dilution in 1× phosphate-buffered saline
(PBS) to reach the desired concentration. Reconstituted peptides were
incubated at 37 °C for up to 24 h for the aggregation studies. Structural
properties of the synthetic homologues at different time points were
assessed by thioﬂavin T binding, 8-anilinonaphthalene-1-sulfonic acid
(ANS; Sigma) binding, andWestern blot (WB) analysis under denatur-
ing and non-denaturing conditions, as described below. For cell culture
experiments, peptides were dissolved to 10 mM in DMSO followed by
the addition of deionized water to 1 mM, and diluted into the pertinent
culture medium at the required concentration.
2.4. Thioﬂavin T binding assay
Binding of the ABri and Bri1–23 homologues (with or without
N-terminal pE) to thioﬂavin T was monitored by ﬂuorescence evalua-
tion as described previously [40,42]. Brieﬂy, 6 μl aliquots from each
50 μM peptide aggregation time point were added to 184 μl of 50 mM
Tris–HCl buffer, pH 8.5, and 10 μl of 0.1 mM thioﬂavin T (Sigma).
Fluorescence was recorded for 300 s in an LS-50B spectrometer (Perkin
Elmer, Waltham, MA) with a slit width of 10 nm and excitation and
emission wavelengths of 435 and 490 nm, respectively [43].
2.5. ANS binding assay
Exposure of hydrophobic residues in the ABri and Bri1–23 peptides
(with or without N-terminal pE) was evaluated by their ability to bind
the ﬂuorescent dye ANS. Fifty microliters from each of the 50 μM pep-
tide aggregation time points were added to 200 μl of PBS, pH 7.4, con-
taining 2 μl of 7.5 mg/ml ANS dissolved in dimethyl formamide
(Sigma). Spectra were recorded from 450 to 570 nm in a Perkin Elmer
LS-50B spectrometer with excitation at 370 nm, slit width of 10 nm,
and a scan speed of 500 nm/min. For each sample, 7 consecutive scans
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were averaged and plotted as ANS binding in arbitrary units of ﬂuores-
cence [44].
2.6. Gel electrophoresis and Western blotting
Peptide aggregation was assessed using the Blue Native PAGE
(BN-PAGE) technique [45]. Brieﬂy, samples were electrophoresed in a
4–13% gradient polyacrylamide gel, in the absence of SDS, with a run-
ning buffer containing 50 mM Tricine, 7.5 mM imidazole, and 0.02%
Coomassie blue G-250 (Sigma) and an anode buffer containing 25 mM
imidazole. Molecular mass was determined using the Amersham
High Molecular Weight Calibration Kit for Native Electrophoresis (GE
Healthcare Life Sciences, Piscataway, NJ) in combination with the low
molecular weight proteins insulin and soybean trypsin inhibitor.
Aggregation was also assessed under denaturing conditions using
16.5% Tris–Tricine SDS gels with a running buffer composed of
100 mM Tris–HCl, 100 mM Tricine, and 0.1% SDS with 200 mM Tris–
HCl used as the anode buffer. Following electrophoretic separation,
proteins were electrotransferred to polyvinylidene ﬂuoride (PVDF)
membranes (0.45 μm pore size; Immobilon, Millipore, Billerica, MA)
at 400mA for 2.5 h using 10mM3-cyclohexylamino-1-propanesulfonic
acid (CAPS, Sigma) buffer, pH 11.0, containing 10% (v/v) methanol. The
membranes were blocked with 5% nonfat milk in Tris-buffered saline
containing 0.1% Tween 20 (TBST) and incubated overnight at 4 °C
with a custom-made rabbit polyclonal antibody speciﬁcally recognizing
the C-terminal portion of the ABri peptide (Ab 338, 1:5000) [14,46,47].
The membranes were immunoreacted with horseradish peroxidase
(HRP)-labeled F(ab′)2 anti-rabbit IgG (1:5000; GE) and developed by
enhanced chemiluminescence (ECL) using the SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientiﬁc, Waltham, MA, USA).
2.7. Cell culture
Human neuroblastoma cells (SH-SY5Y) were obtained from
the American Type Culture Collection (ATCC, Manassas, VA, USA) and
maintained in DMEM medium (Mediatech, Manassas, VA) with 10%
fetal bovine serum (FBS).
2.8. Cell death assays
The extent of apoptosis induced by the ABri and Bri1–23 synthetic
derivatives was evaluated by quantitation of DNA-histone complex
formation resulting from DNA fragmentation using the Cell Death
ELISAplus kit (Roche Applied Science, Indianapolis, IN) as previously
described [40,43,48]. SH-SY5Y cells were seeded at a density of 2 × 104
cells/well on 24-well plates and allowed to attach for 1 day prior to
the addition of 50 μM peptide in DMEM, 0% FBS. Following incubation
for 4 to 24 h, plates were centrifuged for 10min at 1000 RPM (Beckman
J-6B, Beckman Instruments, Fullerton, CA) to collect detached cells. Su-
pernatants were saved for the analyses of lactate dehydrogenase
(LDH) release (see below), and cells were lysed for evaluation of
fragmented DNA–histone complexes (mono- and oligo-nucleosomes)
following the manufacturer's instructions. For LDH quantitation, the su-
pernatants from the peptide-treated cultures were further centrifuged
at 14,000 RPM for 5min to pellet any remaining cell debris, and assayed
with the Cytotoxicity Detection Kit (Roche Applied Science) per the
manufacturer's instructions.
2.9. Immunocytochemical evaluation of cytochrome c subcellular
localization and mitochondrial membrane potential
SH-SY5Y cells were seeded on 12 mm poly-D-lysine coated
glass coverslips (BD Biosciences, Franklin Lakes, NJ) at a density of
7 × 104 cells/coverslip and allowed to attach for 1 day prior to
treatment with 50 μM ABri pE/E, Bri1–23 pE/E, or Aβ42 for 4–16 h.After washing once with cold PBS, cells were ﬁxed with 4% paraformal-
dehyde and blocked with 20 mg/ml BSA in PBS containing 0.3% Triton
X-100. Cells were subsequently incubated with mouse monoclonal
anti-cyt c antibody (BD Biosciences; 1:200 in PBS containing 5 mg/ml
BSA, 2 h at RT) followed by Alexa Fluor 488-conjugated anti-mouse IgG
(Life Technologies, Carlsbad, CA; 1:200 in PBS with 5 mg/ml BSA, 1 h
at RT), and nuclei were counterstained TO-PRO-3 iodide (Life Technolo-
gies; 1:1000 in PBS, 10 min at RT) as previously described. To examine
mitochondrial localization in conjunction with changes in the mem-
brane potential of the organelle, cells – after peptide treatment – were
washed once with warm PBS and incubated for 30 min with 1.5 μM
MitoTracker Red CM-H2X Ros (Life Technologies), followed by cyt c im-
munostaining as above. All images were acquired using a Zeiss LSM 510
confocal microscope and analyzed using ImageJ (NIH, Bethesda, MD;
http://rsbweb.nih.gov).
2.10. Detection of reactive oxygen species
SH-SY5Y cells were seeded at a density of 104 cells/well on 96-well
plates and challenged with 50 μM ABri pE/E for 4 h. The cells were
subsequently incubated at 37 °C with 5 μM CellROX Deep Red (Life
Technologies) and 0.2 μg/ml Hoechst Stain (Immunochemistry
Technologies, Bloomington, MN) followed by ﬁxation in 4% paraformal-
dehyde. Images were acquired using a Nikon Eclipse Ti microscope and
analyzed using ImageJ (NIH).
2.11. Caspase-9 activation and inhibition assays
Caspase-9 activation was measured using the Caspase-Glo 9 lumi-
nescent assay (Promega, Madison, WI). Cells were plated at a density
of 104 cells/well on white 96-well plates with clear bottoms followed
by incubation with freshly solubilized ABri pE at a concentration of
50 μM in DMEM with no FBS for 0–16 h. Caspase-Glo reagent was
added to the cells to promote cell lysis, followed by active caspase cleav-
age of the substrate and generation of a luminescent signal produced by
a luciferase reaction. After 40 minute incubation, the signal, proportion-
al to the amount of caspase activity present, was evaluated on a plate-
reading luminometer (Tecan Freedom Evo 150, Tecan, Männedorf,
Switzerland). To inhibit nonspeciﬁc background activity, the protea-
some inhibitor MG-13 was added to the Caspase-Glo reagent prior to
the experiment as indicated by the manufacturer.
Caspase participation was conﬁrmed through the use of speciﬁc
caspase-9 inhibitor aswell as pan-caspase inhibitors, as describedprevi-
ously [49]. SH-SY5Y cells were seeded at a density of 2 × 104 cells/well
on 24-well plates and allowed to attach for 1 day. Cells were then
challenged with ABri pE (50 μM) or the well-studied apoptosis inducer
staurosporine (Enzo Life Sciences, Farmingdale, NY; 1 μM) in DMEM, 0%
FBS for 8 or 24 h in the presence or absence of 100 μM caspase-9
inhibitor Z-LEHD-FMK (R&D Systems, Minneapolis, MN) or pan-
caspase inhibitor Z-VAD(OMe)-FMK (Enzo Life Sciences). In all cases,
cells were then subjected to Cell Death ELISA as above.
2.12. Statistical analysis
ANOVA for comparison of multiple groups with Tukey post hoc tests
was performed usingGraphPad Prism (GraphPad, La Jolla, CA). Values of
P ≤ 0.05 were considered signiﬁcant.
3. Results
3.1. Structural analysis of ABri and Bri1–23 derivatives
HFIP pre-treatment is known to improve peptide solubilization
while disrupting pre-existing β-sheet-rich structures with the potential
to seed and enhance the process of aggregation. Both parameters were
evaluated by CD spectroscopy to test the inﬂuence of the stop-to-
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cation in the furin-generated BRI2 C-terminal fragments ABri and
Bri1–23. As indicated in Fig. 1A, ABri pE had a different behavior from
the rest of the peptides, showing poor solubility (low CD signal) and re-
sistance to adopt a stable α-helical structure even after the standard
3 day incubation in HFIP, requiring a minimum of 7 day pretreatment
(note the increase of negative signals at 208 and 222 nm as the incuba-
tion time progressed in the left panel). Conversely, ABri E, Bri1–23 pE
and Bri1–23 E all exhibited similar behavior; after 3 days in HFIP, they
generated strong CD signals and reached α-helical structures that
remained unchanged with further incubation time (right panel).
Structural rearrangements in the pretreated peptides generated by
their solubilization in aqueous buffer containing physiologic salt con-
centration were monitored for 2 days while recording changes in the
CD spectra. As illustrated in Fig. 1B, ABri pE andABri E scans (top panels)
were compatible with β-sheet conformations containing some random
structures (minimum centered at ~210 nm instead of the classic
218 nm of pure β-structures). In addition, ABri pE was less stable than
the ABri E homologue; the CD signal faded with time, indicative of the
peptide falling out of solution (top left panel). Notably, Bri1–23 pE
and Bri1–23 E exhibited a primarily random coil conformation (minima
at 198 nm) that remained unchanged throughout the length of the
experiments.
The ﬁbrillization kinetics of the ABri and Bri1–23 with and without
N-terminal pE were analyzed using thioﬂavin T, a dye that displays en-
hanced ﬂuorescence upon binding ﬁbrillar and protoﬁbrillar amyloid
conformations [40,42]. In accordance with their high β-sheet content200 220 240 260
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Fig. 1. Circular dichroism spectroscopyof ABri pE/E and Bri1–23pE/E. Changes in secondary stru
temperature; peptide concentrations of 1 mg/ml) (A) and incubation for up to 48 h in 10mMPO
data represent the mean of 15 scans after subtraction of background readings of the respectivein physiologic salt concentrations, both ABri pE and ABri E showed
thioﬂavin T ﬂuorescence values that increased rapidly and reached a
plateau after only 2 h (Fig. 2A). ABri pE thioﬂavin T ﬂuorescence
remained signiﬁcantly higher than that of ABri E, a trend that continued
for the 24 hour duration of the experiment. In agreement with their
unstructured conformations shown by the CD data, both Bri1–23 pE
and Bri1–23 E displayed negligible binding to thioﬂavin T during the
ﬁrst 24 h of incubation, a trend that remained unaltered when followed
up to 5 days (data not shown). To further evaluate the structural
differences between ABri and Bri1–23 containing either pE or E at
their N-terminus, we examined their binding to the ﬂuorescent molec-
ular probe ANS (Fig. 2B) [50]. When in the presence of hydrophobic
regions, ANS produces an increase in ﬂuorescence intensity and a blue
shift in the emissionmaximum from ~520 nm to ~490 nm. As indicated
in Fig. 2B (left panel), ABri pE displayed a rapid and robust increase in
ANS binding reaching a ﬂuorescence intensity plateau in about 2 h,
with kinetics comparable to that observed with thioﬂavin T. In compar-
ison, ABri E bounds ANS to a lesser degree, whereas Bri1–23 pE and E
did not show a signiﬁcant increase in ﬂuorescence or blue shift to the
emission maximum upon ANS binding for up to 24 h, a trend that
persisted with longer incubation times (data not shown). Fig. 2B
(right panel) illustrates a snap shot of the comparative blue shift in
the ﬂuorescence maximum observed after 24 hour peptide aggregation
for all the peptides tested.
The rapid and distinct aggregation/ﬁbrillization of ABri pE and
ABri E was further visualized by Western blot (WB) as illustrated in
Fig. 2C. Following 0–24 hour aggregation in aqueous-based buffer200 220 240 260
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Fig. 2. Aggregation/ﬁbrillization of ABri pE/E and Bri1–23 pE/E. (A) Oligomerization/ﬁbrillization of ABri pE/E and Bri 1–23 pE/E was assessed by ﬂuorescence evaluation of thioﬂavin T
binding to 50 μMpeptide in 1× PBS over 24 h. (B) Exposure of hydrophobic regions of themoleculewas evaluated by assessing the binding of the peptides to ANS. Left panel: Fluorescence
evaluation in arbitrary units (A.U.); graph illustrates mean ± SEM of three independent experiments after subtraction of blank levels. Right panel: representative scan illustrating ANS
binding curve for ABri pE, ABri E, and Bri 1–23 pE/E at 24 h and highlighting the blue shift of themaximum ﬂuorescence values for ABri pE/E homologues. (C) Blue Native-PAGE. Peptides
were incubated at 20 μM in 1× HBSS at 37 °C for up to 24 h and aliquots at different time-points were separated in a 4–13% Blue Native gel followed byWestern blot analysis. (D) SDS-
PAGE. Peptides were incubated at 20 μM in 1× HBSS at 37 °C for up to 24 h and samples at different time-points were separated in a 5–20% Tris–Tricine SDS gel followed byWestern blot
analysis. All blots were probed with the anti-ABri 338 antibody (1:5000).
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subjected to non-denaturing WB using BN-PAGE [45,51,52]. ABri pE
monomers were polymerized rapidly with the appearance of high
molecular weight oligomers (~200 kD–700 kD) after only 30 min.
These oligomers continued to increase in size over time until 24 h, the lon-
gest incubation time studied, atwhich point very little peptide entered the
gel. ABri E monomers aggregated less aggressively to form intermediate
molecularweight oligomers after 30min, followed by further polymeriza-
tion to form a mixture of intermediate and high molecular weight oligo-
mers that persisted for the 24 h tested. In contrast to ABri pE monomers,
which aggregated extremely fast and were largely nonexistent after the
initial time point, monomers of ABri E remained evident throughout the
24 h of the experiment. Electrophoresis under denaturing conditions
(Fig. 2D) conﬁrmed that both ABri pE and ABri E aggregated rapid-
ly, albeit SDS-resistant ABri pE oligomers reached a higher molecu-
lar mass faster than those of ABri E. It is also important to note that
the oligomeric species present under native conditions had much
higher molecular masses than those seen under denaturing condi-
tions, indicating that most of these aggregates were not SDS-
resistant. Taken together, the enhanced binding of thioﬂavin T
and ANS by ABri peptides compared to Bri1–23 demonstrates that
the structural changes induced by the stop to arginine mutation
originate a peptide more prone to aggregation/ﬁbrillization and
amplify the β-sheet content and hydrophobicity of the molecule.
Also of note, the presence of an N-terminal pyroglutamate on ABri
exacerbates these pro-amyloidogenic structural properties.3.2. ABri pE-induced mitochondrial dysfunction, oxidative stress, and
apoptosis in neuronal cells
DNA fragmentation, an event indicative of apoptosis,was evaluated by
Cell Death ELISA in SH-SY5Y neuronal cells following incubation with the
peptide homologues at 50 μMconcentration, a dose in the lower range of
those typically employed (25–300 μM) for the assessment of amyloid tox-
icity [38,39,53–57]. Although 20 μMwas the lowest concentration of ABri
pE that exhibited ameasurable– albeitmodest– effect in Cell Death ELISA
in our dose–response experimental paradigm (not shown), a 50 μM con-
centration was selected for all the studies described below based on the
well-deﬁned 2.5 fold-change observed over untreated controls. It is im-
portant to emphasize that the actual levels of ABri present in vivo in pa-
renchymal and CAA FBD lesions still remain undeﬁned – as is also the
case for thewidely studiedAβ in AD – although it is clear that the local tis-
sue concentrations are by farmuch higher than the physiological levels of
their soluble counterparts in biological ﬂuids. Discrepancies based on the
different areas of affected brains, genetic variability among patients, years
of disease progression, and differences in the extraction procedures as
well as in the biochemical analysis of the different deposited species con-
tribute to obscure the problem. Among the fewquantitative data available,
the amount of Aβ retrieved fromADbrain deposits could reach an impres-
sive ratio of 140 μg per gramof tissue depending on the brain area selected
for analysis [58]. The complexity of the problem is ampliﬁed by the
uncertainty about the in vivo ratio among the broad spectrum of olig-
omeric species identiﬁed to date and their actual relevance to human
2462 K. Todd et al. / Biochimica et Biophysica Acta 1842 (2014) 2457–2467disease [11], an issue poorly deﬁned in AD and basically unexplored
in FBD.
Fig. 3A illustrates that ABri pE induced nucleosome formation after
only 4 h of peptide challenge, while ABri E was not neurotoxic in the
same time frame. The level of ABri pE-induced apoptosis increased
steadily over time and after 8 and 24 h of peptide challenge the level
of DNA fragmentation rose to about 2-fold and 2.5-fold compared to
control cells that received no peptide treatment, respectively. Cells
treated with the same concentration of Aβ42, the primary component
of AD parenchymal plaques, exhibited apoptotic levels slightly higher
than those of ABri pE-treated cells. Both forms of Bri1–23 did not induce
apoptosis even after 24 h of peptide challenge (Fig. 3A, right panel). LDH
is a cytosolic enzyme that is released into culture medium following
plasma membrane damage, such as during necrotic cell death. None of
the ABri or Bri1–23 peptide variants caused an increase in LDH release
from the neuronal cells, indicating that the plasmamembrane of treated
cells remained intact during the time frame of the experiments (Fig. 3B)
and that neurotoxicity proceeded through an apoptotic mechanism.
Cells treated with Aβ42 showed a slight, albeit not statistically signiﬁ-
cant, increase in LDH release,most likely connected to early stage of sec-
ondary necrosis subsequent to the initiation of apoptosis. Overall, these
results indicate that the stop-to-Arg mutation in BRI2 associated with
FBD, coupled with the N-terminal pE posttranslational modiﬁcation,
renders the ABri peptide neurotoxic via an apoptotic mechanism.
To further delineate the cell death mechanisms engaged by the
peptide variants, cyt c subcellular localizationwas evaluated by confocal
microscopy. Cyt c is a heme protein that is normally present in the
mitochondrial intermembrane space; however during apoptosis cyt c
is released to the cytosol where it plays a key role in the caspase activa-
tion cascade [59]. Fig. 4 demonstrates the punctate localization of cyt c
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Fig. 3.Apoptosis induction byABri pE. SH-SY5Y cellswere challengedwith 50 μMABri pE/E, Bri 1
are expressed as a fold of changeof nucleosome formation compared to no-peptide controls at th
used as ameasure of necrotic cell death. Results are expressed as a fold of change of LDH release
SEM of three independent experiments. ** = p b .01, *** = p b .001.SH-SY5Y cells that is maintained for the 16 h tested. In accordance
with the above Cell Death ELISA results, cells challenged with ABri
pE for only 4 h exhibited diffuse cyt c staining, indicative of its release
from the mitochondria to the cytoplasm. This diffuse staining was
also apparent in cells treated with ABri pE for longer time periods
(8 and 16 h). In contrast, cells incubated with ABri E maintained almost
entirely the mitochondrial cyt c localization consistent with the lack of
neurotoxicity associated with this peptide. Similarly, in cells challenged
with Bri1–23 pE or Bri1–23 E, cyt c remained conﬁned to themitochon-
dria as in the control cells. Cells challenged with Aβ42 exhibited cyt c
release at all time-points studied, in agreement with previous reports
[60–62].
Changes in the mitochondrial membrane potential induced by the
synthetic peptide homologues were illustrated using themitochondrial
marker MitoTracker in conjunction with cyt c immunoﬂuorescence
(Fig. 5). In untreated control SH-SY5Y cells, cyt c maintained a punctate
localization that signiﬁcantly overlappedwith theMitoTracker signal, as
illustrated by themerged images. Thiswas also the case followingABri E
treatment in agreement with the non-proapoptotic behavior of the
peptide. Challenge with ABri pE resulted not only in the release of cyt
c but also in poormitochondrial localization of theMitoTracker stain, in-
dicative of a loss of membrane potential of the organelle. Cells treated
with Aβ42 produced a similar diffuse staining pattern for both cyt c
and MitoTracker. Loss of mitochondrial membrane integrity is often
associated with the generation of reactive oxygen species (ROS) that
are key players in neurodegenerative cellular demise [63–66]. In Fig. 6,
cells treated with ABri pE for only 4 h showed a high level of oxidative
stress, as highlighted by the CellROX ﬂuorogenic probe. Conversely,
cells challenged with ABri E did not show evidence of ROS production,
as with the untreated cells. The fast generation of ROS, visualized
much earlier than other apoptotic markers, suggests that thisours
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Fig. 4.Mitochondrial cytochrome c release. SH-SY5Y cells were challengedwith 50 μMABri pE/E, Bri 1–23 pE/E, or Aβ42 for 4, 8, or 16 h.Green ﬂuorescence indicates cyt c immunostaining;
blue ﬂuorescence represents nuclear DNA counterstained with To-Pro. Magniﬁcation = ×63 in all cases.
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byABri.Whether the different elements in this cascade are differentially
sensitive to peptide dosages remain to be determined.Control ABri pE
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Fig. 5.Mitochondrial dysfunction induced by ABri pE. SH-SY5Y cells were challenged with ABr
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all cases.Mitochondrial dysfunction, such as failure to maintain the appropri-
ate membrane potential, is often associated with the intrinsic apoptotic
pathway. Cyt c release and caspase-9 activation are important steps inABri E Aβ42
i pE/E or Aβ42 for 16 h followed by staining with MitoTracker Red CM-H2XRos and cyt c
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Fig. 6. Oxidative stress in cells challenged with ABri pE. SH-SY5Y cells were treated with 50 μM ABri pE/E for 4 h followed by staining with the CellROX Deep Red ﬂuorogenic probe.
Top panel: Hoechst nuclear stain shown in blue; central panel: oxidized CellROX reagent highlighted in red; Bottom panel: merged images. Magniﬁcation = ×20 in all cases.
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loss of mitochondrial membrane potential and cytochrome c release
seen above, SH-SY5Y cells challenged with ABri pE exhibited caspase-
9 activation that as early as 2 h after peptide treatment (Fig. 7A), provid-
ing additional evidence for the rapid induction of neurotoxicity by this
peptide. Conversely, ABri E did not induce caspase-9 activation consis-
tent with the inability of the peptide to induce an apoptotic response
in this time-frame. Blocking caspase activation with the speciﬁc
caspase-9 inhibitor Z-LEHD-FMK or the pan-caspase inhibitor Z-VAD-A B
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pE for 8 or 24 h (Fig. 7B). Staurosporine, a known inducer of neuronal
apoptosis and activator of caspase-9, was used as a control [70–72].4. Discussion
The most frequent forms of amyloidosis in humans are localized to
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lar and extrapyramidal signs, or a combination of these clinical pheno-
types [73–75]. An important argument supporting the importance of
amyloid in the pathogenesis of these disorders is provided by rare
familial diseases in which the presence of mutated amyloid subunits
is consistently associated with early onset of the disease. In general
terms, familial mutations often result in highly aggregation-prone spe-
cies exhibiting increased hydrophobicity, propensity to form β-sheet
structures, and alterations in peptide charge [76]. This is also the case
with FBD, a disorder that shares many neuropathological and clinical
features with AD in spite of the completely different primary structure
of the respective amyloid subunits. The results presented herein show
that, as a result of the FBD mutation, elongation of the BRI2 cleavage
product by 11 amino acids resulted in the exceptionally amyloidogenic
ABri molecule bearing high β-sheet content and showing rapid oligo-
merization/ﬁbrillization to form high molecular mass oligomers with
increased hydrophobicity when compared to the wild type Bri1–23
counterpart.
Amyloid subunits are known to sustain a number of post-
translational modiﬁcations which in turn largely contribute to the het-
erogeneity of the amyloid deposits. Among themany post-translational
modiﬁcations identiﬁed in systemic and cerebral amyloidosis, phos-
phorylation, isomerization, racemization, oxidation and cyclization
occurring in conjunction with proteolytic fragmentation are the most
relevant [75]. Perhaps the most frequent post-translational modiﬁca-
tion is the formation of pE, a form of blocked N-terminus that precludes
amino acid sequencing using Edman degradation, andwhich is believed
to confer resistance against N-terminal peptidases delaying and/or
preventing the protein removal from the lesions by normal clearance
mechanisms thereby contributing to the accumulation of pathogenic
species in affected tissues [77–79]. The formation of the pyroglutamyl
moiety may result from the post-translational modiﬁcation of either
glutamine or glutamic acid residues. The former is the most common
mechanism and involves the nucleophilic attack of the α-amino group
on the amidated carboxyl group, a reaction catalyzed at neutral pH by
glutaminyl cyclase [21,22]. Although cyclization of N-terminal gluta-
mate by glutaminyl cyclase is not frequent, it interestingly takes place
both in truncated Aβ species, as well as in the ABri and ADan peptides
associated with mutations in the BRI2 gene. The formation of pE has
been reported to alter the physicochemical properties of amyloid pro-
teins favoring aggregation. In the case of ABri, our results demonstrate
that the presence of pE exacerbates the pro-amyloidogenic properties
conferred by the FBD mutation, further enhancing the β-sheet content,
aggregability, and hydrophobicity of the molecule, consistent with the
effect of the posttranslational modiﬁcation in truncated Aβ species
[23,24,32].
Enhanced oligomerization/ﬁbrillization typically correlates with
amyloid-mediated cytotoxicity. In the case of Alzheimer's Aβ, numer-
ous reports illustrate that species containing N-terminal pE are more
toxic than the unmodiﬁed counterparts in cell culture and animal
model paradigms [25,27,29,31]. Further supporting the importance
of posttranslational modiﬁcations for amyloid toxicity, the data pre-
sented herein clearly indicate that when coupled with the FBD muta-
tion, posttranslational pE formation produced high molecular mass
oligomers that induced neuronal cell death within very short time
frames. In addition, our present ﬁndings also demonstrate the lack
of aggregation potential and consequent inability to induce toxicity
of the pE-modiﬁed ABri1–23, arguing against the notion that this
posttranslational modiﬁcation might constitute in itself a general
pathological mechanism triggering amyloid deposition and toxicity
[37].
In contrast to ABri pE, the molecule exhibiting glutamate at the
N-terminus, ABri E, aggregated less aggressively, with slower kinetics,
and did not exhibit signs of toxicity in our experimental paradigm.
Whether this relates to the inability of the peptide to form the
speciﬁc high molecular mass oligomeric assemblies reached by the pEcounterpart remains to be determined. The intermediate hydrophobic-
ity/ﬁbrillization potential of peptide demonstrated in our studies also
suggests that ABri E could contribute to the pathogenesis of the deposits
in alternative ways. In view of the current evidence suggesting that
formation of pE takes place at the site of deposition, both in the brain
and systemic organs [46], it is likely that ABri E is the precursor of the
more pathogenic pE species. Moreover, it is conceivable that the inter-
mediate conformational behavior of ABri E could be tilted to more
amyloidogenic conformations by existing ﬁbrillar structures of ABri pE
acting as seeding elements capable of accelerating and/or enhancing
the formation of more pathogenic elements, a mechanism resembling
the infectivity of prion diseases, which is currently considered as a
signiﬁcant contributor to the mechanisms of AD pathogenesis [80]. In
this light, in vitro and in vivo evidence supporting the seeding capabil-
ities of pE-modiﬁed peptides as well as consequential propagation via
prion-like mechanisms has been presented using truncated forms of
Aβ [28,81] and substantiated by complementary biophysical studies
[82].
Although the exactmechanisms of cellular demise in neurodegener-
ative disorders remain elusive, in the case of AD, a great deal of evidence
points to Aβ-mediated activation of intrinsic and extrinsic apoptotic
pathways [40,83] as key elements for the pathogenesis of the disease.
Intrinsic apoptosis is typically triggered through intracellular stressors
that activate one or more members of the Bcl-2 family of proteins,
leading to pore formation in the outer mitochondrial membrane.
These pores disrupt mitochondrial membrane potential and cause the
release of cyt c, which in turn leads to the formation of the apoptosome
with subsequent activation of caspase-9 and further propagation of the
caspase activation cascade. It is thought that reactive oxygen species
play an important role in the execution of intrinsic apoptosis, either by
providing the intracellular stress required for the initiation of the
cascade or through direct modiﬁcation of the protein components that
facilitate formation of the apoptosome [66]. The data presented herein
demonstrate that ABri pE-mediated toxicity proceeds through an apo-
ptotic mechanism, with levels of DNA fragmentation comparable to
those produced by Aβ42. The process was accompanied by mitochon-
drial compromise with release of cytochrome c, changes in membrane
potential, and induction of oxidative stress mechanisms. The presence
of downstream caspase-9 activation, in addition to the abrogation of
cell death in the presence of speciﬁc caspase-9 inhibitors, conﬁrmed
the involvement of the intrinsic apoptotic pathway.Whethermitochon-
drial engagement results from a direct association of ABri with the
organelle leading to its dysfunction, as shown for Aβ, remains to be
determined [84]. Alternatively, it is conceivable that the initiation of
the intrinsic apoptotic path could originate in a direct interaction of
ABriPE with the plasma membrane and the formation of ion-channel
like structures, aswe previously reported [85], a common feature exhib-
ited also byAβ and other amyloid subunits. Nevertheless, irrespective of
the nature of the initiating events, the similarities in cell death pathways
triggered by ABri and Aβ support the concept that different amyloids,
despite entirely dissimilar origin and primary sequence, can cause sim-
ilar pathological processes that ultimately lead to neurodegeneration
and dementia.
Overall, our data link the induction of amyloid-mediated neuronal
cell apoptosis to the structural stability of the respective subunits.
Through the accelerated and enhanced formation of oligomeric/
pre-ﬁbrillar assemblies, genetic variants and post-translational modiﬁ-
cations exacerbate neuronal dysfunction and accelerate the initiation of
cell death mechanisms engaging mitochondrial pathways. The data
convey the notion that comparable oligomeric amyloid assemblies,
regardless of the primary structure of the amyloid subunit, have the
capacity to elicit common pathological mechanisms that ultimately
result in cell death. Genetic mutations, although rare, through their
accelerated effect and enhanced response constitute unique alterna-
tive models to unveil the mechanisms of amyloid-mediated disease
pathogenesis.
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